Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856284 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,639
- Enrollment target
- 20
- Study locations
NCT00856284: Completed Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Takeda.
NCT00856284 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 2,639 participants, below the 2,940-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00856284, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,639 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
Primary Outcome
The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Glipizide
- DRUG Alogliptin
Study Locations (20)
California
- - Anaheim
- - Artesia
- - Chico
- - Los Alamitos
- - Mission Viejo
- - National City
- - Northridge
- - Pismo Beach
- - Riverside
- - Roseville
- - Sacramento
Arizona
- - Mesa
- - Peoria
- - Phoenix
- - Sierra Vista
- - Tempe
- - Tucson
Alabama
- - Montgomery
- - Muscle Shoals
- - Pell City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,639 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
What the finished NCT00856284 record still lists
NCT00856284 is an interventional study that assigns participants to a tested intervention. Its 2,639 participants enrollment target places it among the larger protocols in the corpus, below the 2,940-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT00856284 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00856284 about?
NCT00856284 is a clinical study titled "Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
What is the current status of trial NCT00856284?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,639 participants. The study started on 2009-03. Estimated completion is 2012-10.
What conditions does trial NCT00856284 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00856284?
The interventions under investigation include: Metformin (DRUG), Glipizide (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00856284?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00856284 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00856284's enrollment target sits among peer trials
2,639 8th of 130 higher than 123 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
- NCT06825715 · 2,653 participants · NA
Multilevel Intervention for Precision Oncology
- NCT05471908 · 2,674 participants · NA
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia